Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Evista
2. Keoxifene
3. Keoxifene Hydrochloride
4. Ly 139481
5. Ly 156758
6. Ly-139481
7. Ly-156758
8. Ly139481
9. Ly156758
10. Raloxifene
11. Raloxifene Hcl
1. 82640-04-8
2. Raloxifene Hcl
3. Evista
4. Keoxifene Hydrochloride
5. Keoxifene
6. Optruma
7. Raloxifene Teva
8. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride
9. Raloxifene (hydrochloride)
10. Ly 156758
11. Ly156758
12. Ly-156758
13. Nsc-706725
14. 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol Hydrochloride
15. Chebi:50740
16. Evista (raloxifene Hydrochloride)
17. 4f86w47br6
18. 6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride
19. Dsstox_cid_14181
20. Dsstox_rid_79119
21. Dsstox_gsid_34181
22. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
23. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
24. Smr000058508
25. Raloxifene Hydrochloride [usan]
26. Ncgc00015889-05
27. Cas-82640-04-8
28. C28h27no4s.hcl
29. Loxifen
30. Unii-4f86w47br6
31. Sr-01000076102
32. Cdt-raloxifene
33. Raloxifene-d4 Hcl
34. Raloxifene Cloridrato
35. Evista (tn)
36. Mfcd01938233
37. Prestwick_1035
38. Raloxifene Hydrochloride [usan:usp]
39. Methanone, Hydrochloride
40. Cloridrato De Raloxifeno
41. Clorhidrato De Raloxifeno
42. Chlorhydrate De Raloxifene
43. Ly139481 Hydrochloride
44. Ly156758 Hydrochloride
45. Chembl1116
46. Schembl19077
47. Mls000859902
48. Mls001332533
49. Mls001332534
50. Mls002222293
51. Raloxifene Hydrochloride, Solid
52. Evista, Raloxifene Hydrochloride
53. Raloxifene Hydrochloride- Bio-x
54. Dtxsid1034181
55. Ly156758 (keoxifene) Hcl
56. Ly-139481 Hcl
57. Hms1570n05
58. Pharmakon1600-01505622
59. Amy23426
60. Bcp05713
61. Raloxifene Hydrochloride (jan/usp)
62. Tox21_110255
63. Tox21_302369
64. Tox21_501051
65. Hy-13738a
66. Nsc706725
67. Nsc759285
68. Raloxifene Hydrochloride [mi]
69. S1227
70. Raloxifene Hydrochloride [jan]
71. Akos008131940
72. Tox21_110255_1
73. Ac-8390
74. Ccg-213497
75. Cs-1775
76. Ds-2162
77. Ks-1102
78. Lp01051
79. Nc00665
80. Nsc 706725
81. Nsc 759285
82. Nsc-759285
83. Raloxifene Hydrochloride [mart.]
84. Raloxifene Hydrochloride [vandf]
85. Ncgc00015889-03
86. Ncgc00015889-11
87. Ncgc00092353-01
88. Ncgc00092353-03
89. Ncgc00094334-01
90. Ncgc00094334-02
91. Ncgc00255153-01
92. Ncgc00261736-01
93. Raloxifene Hydrochloride [usp-rs]
94. Raloxifene Hydrochloride [who-dd]
95. Br164310
96. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride
97. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)
98. Raloxifene Hydrochloride [ema Epar]
99. Eu-0101051
100. Ft-0630912
101. R0109
102. Sw197106-5
103. En300-52517
104. Raloxifene Hydrochloride [orange Book]
105. D02217
106. R 1402
107. Raloxifene Hydrochloride [ep Monograph]
108. Raloxifene Hydrochloride [usp Impurity]
109. Raloxifene Hydrochloride [usp Monograph]
110. 640r048
111. A840401
112. Q-201656
113. Sr-01000076102-2
114. Sr-01000076102-9
115. Q27122215
116. (6-oxo-1,6-dihydro-pyridazin-3-yloxy)-aceticacid
117. Raloxifene Hydrochloride, European Pharmacopoeia (ep) Reference Standard
118. Raloxifene Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
119. Raloxifene Hydrochloride, United States Pharmacopeia (usp) Reference Standard
120. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride
121. (6-oh-2-(4-oh-ph)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)ph)methanone Hydrochloride
122. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone Hydrochloride
123. [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
124. [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
125. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride
126. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone, Monohydrochloride
127. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
128. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
129. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
130. [6-hydroxy-2[4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
131. 1-[2-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperidinium Chloride
132. 6-hydroxy-2-(4-hydroxyphenyl)-3-[ 4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, Hydrochloride
133. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]-thiophene Hydrochloride
134. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene Hydrochloride
135. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Methanone Hydrochloride
136. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Ketone Hydrochloride
137. 6-hydroxy-2-(p-hydroxyphenyl)benzo(.beta.)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride
138. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(.beta.)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride
139. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, Hydrochloride (1:1)
140. Raloxifene Hydrochloride For Peak Identification, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 510.0 g/mol |
---|---|
Molecular Formula | C28H28ClNO4S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 509.1427572 g/mol |
Monoisotopic Mass | 509.1427572 g/mol |
Topological Polar Surface Area | 98.2 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 655 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Evista |
PubMed Health | Raloxifene (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Lilly |
2 of 4 | |
---|---|
Drug Name | Raloxifene hydrochloride |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Tentative Approval; Prescription |
Company | Teva Pharms Usa; Invagen Pharms; Watson Labs |
3 of 4 | |
---|---|
Drug Name | Evista |
PubMed Health | Raloxifene (By mouth) |
Drug Classes | Antineoplastic Agent, Endocrine-Metabolic Agent |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Lilly |
4 of 4 | |
---|---|
Drug Name | Raloxifene hydrochloride |
Drug Label | EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m... |
Active Ingredient | Raloxifene hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | 60mg |
Market Status | Tentative Approval; Prescription |
Company | Teva Pharms Usa; Invagen Pharms; Watson Labs |
Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5. 1).
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Selective Estrogen Receptor Modulators
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Estrogen Antagonists
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)
G03XC01
G03XC01
G03XC01
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-02
Pay. Date : 2013-03-22
DMF Number : 16143
Submission : 2002-09-23
Status : Active
Type : II
Certificate Number : R1-CEP 2014-054 - Rev 01
Issue Date : 2023-03-31
Type : Chemical
Substance Number : 2375
Status : Valid
Date of Issue : 2025-07-25
Valid Till : 2028-06-16
Written Confirmation Number : WC-0034
Address of the Firm :
Registrant Name : Alvogen Korea Co., Ltd.
Registration Date : 2020-09-17
Registration Number : 20200917-209-J-745
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri Venkateswara Co-operative Industrial Estate Bollaram, Jinnaram Mandal, Sangareddy District, Telangana, 502325 India
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-04-29
Pay. Date : 2014-02-24
DMF Number : 27969
Submission : 2014-03-17
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21327
Submission : 2008-02-11
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-03-15
Pay. Date : 2013-09-11
DMF Number : 27064
Submission : 2013-05-06
Status : Active
Type : II
Date of Issue : 2022-09-01
Valid Till : 2025-07-02
Written Confirmation Number : WC-0074Amended
Address of the Firm :
NDC Package Code : 65691-0079
Start Marketing Date : 2013-05-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-10-07
Pay. Date : 2015-09-22
DMF Number : 29721
Submission : 2015-09-24
Status : Active
Type : II
Certificate Number : R1-CEP 2015-171 - Rev 00
Issue Date : 2022-04-08
Type : Chemical
Substance Number : 2375
Status : Valid
Registration Number : 303MF10064
Registrant's Address : Strada Rivoltana Km. 6/7 20053 Rodano (MI), Italy
Initial Date of Registration : 2021-04-13
Latest Date of Registration :
NDC Package Code : 17337-0071
Start Marketing Date : 2019-08-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-09-14
Pay. Date : 2017-08-01
DMF Number : 31952
Submission : 2017-08-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41611
Submission : 2025-03-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39175
Submission : 2023-11-29
Status : Active
Type : II
Certificate Number : CEP 2023-432 - Rev 00
Issue Date : 2024-12-11
Type : Chemical
Substance Number : 2375
Status : Valid
Date of Issue : 2023-07-24
Valid Till : 2026-08-23
Written Confirmation Number : WC-0381
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21650
Submission : 2008-05-22
Status : Active
Type : II
Date of Issue : 2022-08-10
Valid Till : 2025-05-08
Written Confirmation Number : WC-0219
Address of the Firm :
NDC Package Code : 62704-0115
Start Marketing Date : 1998-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Certificate Number : R1-CEP 2014-054 - Rev 01
Status : Valid
Issue Date : 2023-03-31
Type : Chemical
Substance Number : 2375
Raloxifene Hydrochloride, Modified Process
Certificate Number : CEP 2024-069 - Rev 00
Status : Valid
Issue Date : 2024-04-24
Type : Chemical
Substance Number : 2375
Certificate Number : CEP 2012-016 - Rev 02
Status : Valid
Issue Date : 2024-01-05
Type : Chemical
Substance Number : 2375
Certificate Number : CEP 2022-165 - Rev 00
Status : Valid
Issue Date : 2024-04-22
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2010-205 - Rev 00
Status : Valid
Issue Date : 2017-09-06
Type : Chemical
Substance Number : 2375
Raloxifene Hydrochloride, LAXAI
Certificate Number : CEP 2023-123 - Rev 00
Status : Valid
Issue Date : 2023-11-29
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2010-227 - Rev 01
Status : Valid
Issue Date : 2019-10-15
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2011-349 - Rev 00
Status : Valid
Issue Date : 2020-11-30
Type : Chemical
Substance Number : 2375
Certificate Number : R0-CEP 2015-174 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2016-11-02
Type : Chemical
Substance Number : 2375
Certificate Number : R1-CEP 2015-171 - Rev 00
Status : Valid
Issue Date : 2022-04-08
Type : Chemical
Substance Number : 2375
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Raloxifene Hydrochloride USP/Ph. Eur.
Date of Issue : 2025-07-25
Valid Till : 2028-06-16
Written Confirmation Number : WC-0034
Address of the Firm : Unit II, Plot Nos. 1, 75A, 75B, 105, 110, 111 & 112, Sri Venkateswara Co-operati...
Date of Issue : 2022-08-10
Valid Till : 2025-05-08
Written Confirmation Number : WC-0219
Address of the Firm : Plot No. E-22, MIDC Tarapur-Boisar, Thane-401506, Maharashtra, India
Raloxifene Hydrochloride Ph.Eur
Date of Issue : 07-11-2025
Valid Till : 25-06-2028
Written Confirmation Number : WC-0023
Address of the Firm : Sy. No’s. 52,53,58,59,61 to 78, 127 & 128,Pydibhimavaram Village & Sy. No’s....
Raloxefene hydrochloride Ph.Eur/USP
Date of Issue : 2022-09-19
Valid Till : 2025-07-02
Written Confirmation Number : WC-0119
Address of the Firm : Plot No. 35, 36, 38, 39, 40, 49, 50 & 51, Phase-IV, IDA, Jeedimetla, Medchal-Mal...
Date of Issue : 2022-09-01
Valid Till : 2025-07-02
Written Confirmation Number : WC-0074Amended
Address of the Firm : 294, GIDC Estate Ankleshwar, Bharuch-393002, Gujarat India
Raloxifene Hydrochloride USP/Ph.Eur
Date of Issue : 2022-09-30
Valid Till : 2025-08-08
Written Confirmation Number : WC-0066
Address of the Firm : Plot No 1, Hetero Infrastructure SEZ Ltd., N. Narasapuram, Anakapalli -531081, A...
Date of Issue : 2023-07-24
Valid Till : 2026-08-23
Written Confirmation Number : WC-0381
Address of the Firm : Plot No. 98-99, Sector-1, Industrial Area Pithampur, Dhar-454775, Madhya Pradesh...
Raloxifene Hydrochloride BP/Ph. Eur
Date of Issue : 2023-07-10
Valid Till : 2025-05-21
Written Confirmation Number : WC-0313
Address of the Firm : SurveyNo.247,Choutuppal, Choutuppal (V),Choutuppal (M),YadadriBhuvanagiri Distri...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Alvogen Korea Co., Ltd.
Registration Date : 2020-09-17
Registration Number : 20200917-209-J-745
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...
Registrant Name : Medipoem Co., Ltd.
Registration Date : 2025-06-23
Registration Number : 20231218-209-J-1584(A)
Manufacturer Name : Aurore Pharmaceuticals Priva...
Manufacturer Address : Plot No. 35, 36, 38 to 40 & 49 to 51 Phase-IV, IDA, Jeedimetla, Hyderabad Telangana, ...
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-08-13
Registration Number : 20200813-209-J-694
Manufacturer Name : Cambrex Profarmaco Milano Sr...
Manufacturer Address : Via Curiel, 34 – 20067 Paullo (Milan) Italy
Raloxifene hydrochloride monohydrate
Registrant Name : Dasan Pharmaceutical Co., Ltd.
Registration Date : 2017-11-07
Registration Number : 20171107-209-J-123
Manufacturer Name : Dasan Pharmaceutical Co., Lt...
Manufacturer Address : 342 Deokamsan-ro, Dogomyeon, Asan-si, Chungcheongnam-do @ 28, Yakjakgongdan 2-gil, Hy...
Registrant Name : Hanmi Precision Chemical Co., Ltd.
Registration Date : 2022-10-24
Registration Number : 20221024-209-J-1389
Manufacturer Name : Hanmi Precision Chemical Co....
Manufacturer Address : 57 Gyeongje-ro, Siheung-si, Gyeonggi-do (1248-10)
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2021-10-14
Registration Number : 20211014-209-J-1021
Manufacturer Name : Hetero Drugs Limited(Unit-IX...
Manufacturer Address : Plot No.1, Hetero Infrastructure-SEZ Ltd, N. Narasapuram Village, Nakkapalli Mandal, ...
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2018-02-27
Registration Number : 20180227-209-J-77
Manufacturer Name : Kyungbo Pharmaceutical Co., ...
Manufacturer Address : 174 Silok-ro, Asan-si, Chungcheongnam-do
Registrant Name : Engichem Life Sciences Co., Ltd.
Registration Date : 2020-07-16
Registration Number : 20200716-209-J-693
Manufacturer Name : Engichem Life Sciences Co., ...
Manufacturer Address : 59 Biovalley-ro, Jecheon-si, Chungcheongbuk-do
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 62704-0115
Start Marketing Date : 1998-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65862-714
Start Marketing Date : 2024-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65691-0079
Start Marketing Date : 2013-05-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12828-0085
Start Marketing Date : 2011-01-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 63419-0420
Start Marketing Date : 2008-10-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49706-1723
Start Marketing Date : 2010-01-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 24234-0008
Start Marketing Date : 2023-11-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0065
Start Marketing Date : 1997-12-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0071
Start Marketing Date : 2019-08-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53183-4005
Start Marketing Date : 2010-09-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...
About the Company : Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies in India. Over the past six decades, we have been developing and manufacturing affordable ...
About the Company : Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. With over 35 years...
About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...
About the Company : ERREGIERRE, a family company, was founded in 1974 and today is one of the leading Italian active pharmaceutical ingredients manufactures for human and veterinary use. In ERREGIE...
About the Company : Since its foundation in 1959, JEIL Pharm established. its own central research laboratory for the formulation and synthesis of drugs, followed by its successive construction of KGM...
About the Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most prestigious pharma co...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2022
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé'...
Details : Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2022
Details:
AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Societal CDMO
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2022
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Societal CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2022
Details:
Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: AmyriAD
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 06, 2022
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : AmyriAD
Deal Size : $1.0 million
Deal Type : Agreement
Details : Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 06, 2022
Details:
Undisclosed
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2021
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 29, 2021
Details:
AD101 was initially discovered in phenotypic testing of animal models of learning and memory. It also improved learning and memory in models dependent on Aβ and tau while reducing the accumulation of both biomarkers in these animals.
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2021
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AD101 was initially discovered in phenotypic testing of animal models of learning and memory. It also improved learning and memory in models dependent on Aβ and tau while reducing the accumulation of both biomarkers in these animals.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2021
Details:
This agreement covers the exchange of clinical and nonclinical trial information related to COVID-19 treatment using the repurposed Raloxifene molecule developed by five research organisations from the EU and South Korea.
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: CINECA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 18, 2020
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : CINECA
Deal Size : Undisclosed
Deal Type : Agreement
Details : This agreement covers the exchange of clinical and nonclinical trial information related to COVID-19 treatment using the repurposed Raloxifene molecule developed by five research organisations from the EU and South Korea.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 18, 2020
Details:
A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate4Cov’s guidelines.
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2020
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2020
Details:
Undisclosed
Lead Product(s): Raloxifene Hydrochloride,Vitamin D3,AD-102
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2019
Lead Product(s) : Raloxifene Hydrochloride,Vitamin D3,AD-102
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2019
Details:
Undisclosed
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2018
Lead Product(s) : Raloxifene Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 05, 2018
Details:
Undisclosed
Lead Product(s): Raloxifene Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 01, 2018
Lead Product(s) : Raloxifene Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2018
6-Methoxy-2-(4-Methoxy Phenyl) Benzo(B)Thiophene
CAS Number : 63675-74-1
End Use API : Raloxifene Hydrochloride
About The Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It ...
4-(2-Piperidino Ethoxy) Benzoic Acid HCl
CAS Number : 84449-80-9
End Use API : Raloxifene Hydrochloride
About The Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It ...
4-(2-Piperidinoethoxy)benzoyl chloride, HCl
CAS Number : 84449-81-0
End Use API : Raloxifene Hydrochloride
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
4-(2-Piperidinyl)Ethoxy)Benzoic Acid Hydrochloride
CAS Number : 84449-80-9
End Use API : Raloxifene Hydrochloride
About The Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in...
4-(2-Piperidin-1-yl-ethoxy)benzoic acid hydrochlor...
CAS Number : 1246815-60-0
End Use API : Raloxifene Hydrochloride
About The Company : TEXLAB INDUSTRIES was established in 1971, manufacturing & trading related business. TEXLAB INDUSTRIES - company launched by Late Shree AMBALAL MISTRY for local...
6-Methoxy-2-(4-methoxyphenyl) benzo [b] thiophene
CAS Number : 63675-74-1
End Use API : Raloxifene Hydrochloride
About The Company : TEXLAB INDUSTRIES was established in 1971, manufacturing & trading related business. TEXLAB INDUSTRIES - company launched by Late Shree AMBALAL MISTRY for local...
6-methoxy-2-(4-methoxyphenol) benzo[b]thiophene
CAS Number : 63675-74-1
End Use API : Raloxifene Hydrochloride
About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...
2-(4-hydroxyphenyl)benzo[b] thiophene-6-ol
CAS Number : 63676-22-2
End Use API : Raloxifene Hydrochloride
About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...
2-[4-(methylsulfonyl)oxy]phenyl]benxo (b) thiophen...
CAS Number : 84449-65-0
End Use API : Raloxifene Hydrochloride
About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...
6-methoxy-2-(4-methoxyphenyl) benzo([b]thiophene
CAS Number : 63675-74-1
End Use API : Raloxifene Hydrochloride
About The Company : We believe in attaining the highest levels of customer satisfaction and social welfare with the philosophy of keeping first things first. Our systematic interve...
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
42
PharmaCompass offers a list of Raloxifene Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Raloxifene Hydrochloride manufacturer or Raloxifene Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Raloxifene Hydrochloride manufacturer or Raloxifene Hydrochloride supplier.
PharmaCompass also assists you with knowing the Raloxifene Hydrochloride API Price utilized in the formulation of products. Raloxifene Hydrochloride API Price is not always fixed or binding as the Raloxifene Hydrochloride Price is obtained through a variety of data sources. The Raloxifene Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Raloxifene Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Raloxifene Hydrochloride, including repackagers and relabelers. The FDA regulates Raloxifene Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Raloxifene Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Raloxifene Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Raloxifene Hydrochloride supplier is an individual or a company that provides Raloxifene Hydrochloride active pharmaceutical ingredient (API) or Raloxifene Hydrochloride finished formulations upon request. The Raloxifene Hydrochloride suppliers may include Raloxifene Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Raloxifene Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Raloxifene Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Raloxifene Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Raloxifene Hydrochloride DMFs exist exist since differing nations have different regulations, such as Raloxifene Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Raloxifene Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Raloxifene Hydrochloride USDMF includes data on Raloxifene Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Raloxifene Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Raloxifene Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Raloxifene Hydrochloride Drug Master File in Japan (Raloxifene Hydrochloride JDMF) empowers Raloxifene Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Raloxifene Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Raloxifene Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Raloxifene Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Raloxifene Hydrochloride Drug Master File in Korea (Raloxifene Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Raloxifene Hydrochloride. The MFDS reviews the Raloxifene Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Raloxifene Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Raloxifene Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Raloxifene Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Raloxifene Hydrochloride suppliers with KDMF on PharmaCompass.
A Raloxifene Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Raloxifene Hydrochloride Certificate of Suitability (COS). The purpose of a Raloxifene Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Raloxifene Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Raloxifene Hydrochloride to their clients by showing that a Raloxifene Hydrochloride CEP has been issued for it. The manufacturer submits a Raloxifene Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Raloxifene Hydrochloride CEP holder for the record. Additionally, the data presented in the Raloxifene Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Raloxifene Hydrochloride DMF.
A Raloxifene Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Raloxifene Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Raloxifene Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Raloxifene Hydrochloride written confirmation (Raloxifene Hydrochloride WC) is an official document issued by a regulatory agency to a Raloxifene Hydrochloride manufacturer, verifying that the manufacturing facility of a Raloxifene Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Raloxifene Hydrochloride APIs or Raloxifene Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Raloxifene Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Raloxifene Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Raloxifene Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Raloxifene Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Raloxifene Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Raloxifene Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Raloxifene Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Raloxifene Hydrochloride suppliers with NDC on PharmaCompass.
Raloxifene Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Raloxifene Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Raloxifene Hydrochloride GMP manufacturer or Raloxifene Hydrochloride GMP API supplier for your needs.
A Raloxifene Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Raloxifene Hydrochloride's compliance with Raloxifene Hydrochloride specifications and serves as a tool for batch-level quality control.
Raloxifene Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Raloxifene Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Raloxifene Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Raloxifene Hydrochloride EP), Raloxifene Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Raloxifene Hydrochloride USP).